Sila Algül is a PhD candidate at the Department of Physiology at the Amsterdam UMC location, under the supervision of Prof. Jolanda van der Velden and Dr. Diederik Kuster (funded by LeDucq)
During her bachelor’s internship at the Physiology Department in Amsterdam, Sila developed a profound interest in cardiomyopathies and human in vitro models. Her subsequent VU research fellowship further potentiated her interest for translational cardiovascular research. As a master’s student (Cardiovascular Research, VUmc School of Medical Sciences) she also joined the Medical Biology department at the Amsterdam UMC for her master’s internship and her literature study, with which she delved into cardiac electrophysiology and cardiac gene therapy. She now thoroughly enjoys connecting the dots: be it ideas from different disciplines, people from different teams, or applications from different industries, but especially within the field of cardiomyopathies and electrophysiological abnormalities. By oscillating between these facets of research, she aspires to bridge the translational gap and to help patients through her work.
Floor van den Dolder is a PhD candidate at the Department of Physiology at the Amsterdam UMC location, under the supervision of Prof. Jolanda van der Velden and Dr. Diederik Kuster. Her research is positioned under the Dutch Cardioascular Alliance (DCVA) within the Double Dose consortium.
After obtaining her master’s degree (Biology of Disease, Utrecht University), Floor worked as a technician for a year at the UMC Utrecht generating patient specific induced pluripotent stem cells (iPSC) and iPSC derived cardiomyocytes. Together with her Master internships at the Pathology department UMC Utrecht, Cardiothoracic Surgery/ Experimental Cardiology UMC Utrecht, Center for Minimal Invasive Therapeutics (C-MIT) within the California NanoSystems Institute UCLA, and the Genetics UMC Utrecht, she developed her interest into generating reliable advanced human in vitro models (2D culture, hydrogels, engineered heart tissue, and microfluidic systems) to study the genetic heart diseases. Linking clinical data, patients’ samples, in vitro and in vivo models, she aims to be able to unravel the clinical heterogeneity between individuals within specific genetic cardiomyopathies and thereby translating the results back to the clinic.